China is reportedly tapping into America’s growing appetite for performance-enhancing compounds by expanding into the online peptide market, according to new blockchain analysis and federal health officials. The issue is drawing fresh attention as the Food and Drug Administration prepares to review whether several peptides should be added to the Section 503A Bulks List, a decision that could affect how medical professionals use these substances in compounded prescriptions.
The FDA’s Pharmacy Compounding Advisory Committee is scheduled to meet Thursday and Friday to consider seven peptides that are commonly described as protein-building chemicals. The review comes as blockchain analysis firm Chainalysis reported that at least one Chinese manufacturer previously linked to the production of opioids, including fentanyl, has shifted into selling peptides online. Axios first reported the findings on July 7.
According to Chainalysis, Chinese-based companies generated roughly $27 million in peptide sales during the first quarter of 2026. That represents a 150% increase compared to the previous quarter. The report noted that cryptocurrency has become a preferred payment method for many of these transactions because it is more difficult to trace than traditional banking channels.
Sara Graham, a senior intelligence analyst at Chainalysis, said the transition appears to have been driven by business incentives rather than ideology. She explained that manufacturers facing the possibility of U.S. sanctions or criminal charges in the opioid trade found an attractive alternative in the rapidly expanding peptide market, where consumer demand has grown significantly.
That demand has been fueled in part by the explosion of health and fitness content across social media. A Pew Research Center study published in May found that roughly half of American adults now receive health advice from wellness influencers online. The popularity of muscle-building compounds, weight-loss drugs, and other performance-enhancing products has created a large customer base willing to seek out products outside traditional medical channels.
Federal health officials continue to warn consumers about the risks involved. An HHS spokesperson told the Daily Caller News Foundation that the Trump administration remains committed to ensuring that drugs sold in the United States meet applicable safety standards. The spokesperson said the FDA continues to use warning letters, import controls, inspections, product seizures, injunctions, and coordination with federal, state, and international partners to combat the illegal marketing and distribution of unapproved drugs, including peptides intended for human use.
The FDA has previously cautioned against purchasing unapproved GLP-1 medications and other compounded drugs from questionable sources. Officials have warned that counterfeit or improperly manufactured products may not meet the same safety and quality standards as FDA-approved medications such as Ozempic or Trulicity.
Nora Khaldi, CEO of peptide research company Nuritas, expressed alarm over the risks consumers are taking. She said she was “gobsmacked” by the willingness of people to use compounds without knowing how they were produced or whether they meet basic quality standards. Even when a peptide itself has legitimate scientific potential, she said, there is no substitute for knowing exactly what is in the product being consumed.
